You are here

  • Home
  • Archive
  • Volume 77, Issue 6
  • Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Concise report
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
Annals of the Rheumatic Diseases 2018;77:914-921.